C the Signs, the creator of an Artificial Intelligence (AI)-based platform to identify patients at risk of cancer at the earliest and most curable stage, today announced £6.4m in funding from Khosla Ventures. The new capital will accelerate the company’s expansion from the United Kingdom, where it has already helped detect tens of thousands of cancers across the National Health Service (NHS), to the United States.
C the Signs fills a critical gap between cancer screening, which can be costly and imprecise for all but the most common forms of cancer, and diagnostic tests which are often ordered only after patients present with symptoms. The company’s explainable AI model works by analysing data already available in patient electronic health records, going beyond basic risk indicators like age and gender, to examine a wide number of personal and environmental data points to precisely assess an individual’s cancer risk. By personalising risk profiles, the platform flags people who need targeted testing and rules out those who do not, reducing the burden on primary care physicians.
That approach has already proven successful in the NHS, where it has identified 20.7% of breast cancer cases up to five years earlier than standard pathways, as well as beating early-stage diagnoses of ovarian cancer using traditional methods by 53.3%. C the Signs also recently unveiled new data at the 2025 ASCO Gastrointestinal Cancers Symposium using its AI model on the records of 894,275 patients registered in the Mayo Data Platform to achieve a sensitivity of 93.8% – comparable to the sensitivity level of a colonoscopy – and a specificity of 19.7% in identifying patients at risk of colorectal cancer. By detecting tumours when they can still be treated at stage 1 or 2, C the Signs increases survival odds compared to later-stage diagnoses.
